Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 5;18(1):1.
doi: 10.1186/s40360-016-0111-8.

Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids

Luca Parente  1
Affiliations
Review

Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids

Luca Parente. BMC Pharmacol Toxicol. .

Abstract

Background: Deflazacort is a synthetic corticosteroid characterized by a favourable pharmacokinetic profile, peculiar pharmacodynamic properties and a good safety profile. However, to the best of our knowledge, no dose-conversion table based on direct comparison of relative potencies between deflazacort and other main corticosteroids is currently available in scientific literature.

Main body: This paper, while reporting a brief review of deflazacort pharmacological properties, its efficacy and tolerability in different clinical areas, has been designed with the specific aim of providing a new dose-conversion table of corticosteroids, including for the first time also deflazacort.

Short conclusion: We suggest that this new conversion table could be a useful tool for physicians who need to select the appropriate dose of deflazacort in their clinical practice.

Keywords: Corticosteroids; Deflazacort; Equipotency ratio; Relative potencies; Therapeutic efficacy; Tolerability.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structures of prednisolone and deflazacort [3]
See this image and copyright information in PMC

References

    1. Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In : Hardman JG, Limbird LE : Goodman & Gilman’s - The Pharmacological Basis of Therapeutics 10th Edition. New York: McGraw-Hill; 2001. p.1649-1677.
    1. Scremin A, Piazzon M, Segatto Silva MA, Gislaine Kuminek G, et al. Spectrophotometric and HPLC determination of deflazacort in pharmaceutical dosage forms. Braz. J. Pharm. Sci. 2010;46(2):281–87. doi: 10.1590/S1984-82502010000200015. - DOI
    1. Markham A, Bryson HM. Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50(2):317–33. doi: 10.2165/00003495-199550020-00008. - DOI - PubMed
    1. Assandri A, Buniva G, Martinelli E, Perazzi A, Zerilli L. Pharmacokinetics and metabolism of Deflazacort in the rat, dog, monkey and man. Adv Exp Med Biol. 1984;171:9–23. - PubMed
    1. Luzzani F, Glasser A. Differential binding “in vitro” to glucocorticoid receptors of deflazacort and prednisolone. Eur J Pharmacology. 1981;76:427-30. - PubMed

MeSH terms